

Alison D Marshall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1185777/publications.pdf>

Version: 2024-02-01

26
papers

1,137
citations

623734

14
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

1336
citing authors

#	ARTICLE	IF	CITATIONS
1	â€œIt's a revolving doorâ€: Ego-depletion among prisoners with injecting drug use histories as a barrier to post-release success. <i>International Journal of Drug Policy</i> , 2022, 101, 103571.	3.3	7
2	â€œNot just one box that you tick offâ€™ â€œ Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective. <i>International Journal of Drug Policy</i> , 2022, 102, 103610.	3.3	5
3	Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment. <i>Drug and Alcohol Dependence</i> , 2022, 235, 109438.	3.2	6
4	Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 426-445.	8.1	50
5	A gender lens is needed in hepatitis C elimination research. <i>International Journal of Drug Policy</i> , 2022, 103, 103654.	3.3	10
6	A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. <i>Viruses</i> , 2022, 14, 1555.	3.3	7
7	Structural competency in the post-prison period for people who inject drugs: A qualitative case study. <i>International Journal of Drug Policy</i> , 2021, 95, 103261.	3.3	15
8	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. <i>International Journal of Drug Policy</i> , 2021, 96, 103469.	3.3	7
9	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs preâ€•and postâ€•universal access to directâ€•acting antiviral treatment in Australia: The LiveRLife study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 281-293.	2.0	39
10	Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialistsâ€”The practitioner experience. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107705.	3.2	40
11	Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. <i>International Journal of Drug Policy</i> , 2020, 86, 102964.	3.3	5
12	Enhancing engagement in hepatitis C care among people who inject drugs. <i>Addiction</i> , 2019, 114, 2104-2106.	3.3	4
13	Do women with complex alcohol and other drug use histories want womenâ€•only residential treatment?. <i>Addiction</i> , 2018, 113, 989-997.	3.3	31
14	Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. <i>Journal of Infectious Diseases</i> , 2018, 217, 1889-1896.	4.0	88
15	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 125-133.	8.1	128
16	The 7th Canadian Symposium on Hepatitis C Virus: â€œToward Elimination of HCV: How to Get Thereâ€•. <i>Canadian Liver Journal</i> , 2018, 1, 139-152.	0.9	3
17	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. <i>International Journal of Drug Policy</i> , 2018, 61, 23-30.	3.3	57
18	Building on feminist achievements to enhance choice for women seeking treatment. <i>Addiction</i> , 2018, 113, 1001-1002.	3.3	0

#	ARTICLE	IF	CITATIONS
19	The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. <i>Journal of Hepatology</i> , 2018, 69, 1188-1196.	3.7	78
20	Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 514-520.	8.1	123
21	“I didn’t want to let it go too far.” The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. <i>International Journal of Drug Policy</i> , 2017, 47, 153-160.	3.3	10
22	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. <i>CMAJ Open</i> , 2016, 4, E605-E614.	2.4	74
23	Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. <i>International Journal of Drug Policy</i> , 2015, 26, 984-991.	3.3	50
24	Ottawa Panel Evidence-Based Clinical Practice Guidelines for the Management of Osteoarthritis in Adults Who Are Obese or Overweight. <i>Physical Therapy</i> , 2011, 91, 843-861.	2.4	79
25	Ottawa Panel Evidence-Based Clinical Practice Guidelines for Strengthening Exercises in the Management of Fibromyalgia: Part 2. <i>Physical Therapy</i> , 2008, 88, 873-886.	2.4	87
26	Ottawa Panel Evidence-Based Clinical Practice Guidelines for Aerobic Fitness Exercises in the Management of Fibromyalgia: Part 1. <i>Physical Therapy</i> , 2008, 88, 857-871.	2.4	127